Table 1.

Distribution of sociodemographic, clinical, and behavioral characteristics of suspected cases according to the results of the mpox real-time polymerase chain reaction, Centro de Referência e Treinamento DST/Aids, June 18 to September 20, 2022.

Characteristics	Mpox real-time polymerase chain reaction
	Undetectable		Detectable		Total		P-value
	(n = 85; 21.6%)		(n = 309; 78.4%)		(n = 394; 100.0%)
	n	%	n	%	n	%
Sex assigned at birth							<0.001
Male	76	89.4	309	100.0	385	97.7
Female	9	10.6	0	0.0	9	2.3
Age group (years old)							0.01
≤ 24	12	14.1	22	7.1	34	8.6
25 - 39	44	51.8	212	68.6	256	65.0
≥ 40	29	34.1	75	24.3	104	26.4
Race/Ethnicitya							0.823
White	49	57.6	164	53.1	213	54.1
Black	15	17.6	52	16.8	67	17.0
Asian	1	1.2	2	0.6	3	0.8
Pardo (mixed)	20	23.5	86	27.8	106	26.9
Indigenous	0	0.0	2	0.6	2	0.5
Gender and sexual orientation							<0.001
Heterosexual	16	18.8	4	1.3	20	5.1
Man who have sex with men/ bisexual, or transgender woman	69	81.2	305	98.7	374	94.9
Years of studyb							0.113
Up to 11	40	48.8	114	39.0	154	41.2
12 or more	42	51.2	178	61.0	220	58.8
Patient category							0.02
People living with HIV/AIDS	52	61.2	168	54.4	220	58.8
PrEP user	15	17.6	99	32.0	114	28.9
Non-HIV / Non-PrEP	18	21.2	42	13.6	60	15.2
Status according HIV infectionc							0.371
VL < 50 copies/ml / CD4 < 350 cells/mm3	4	7.7	7	4.2	11	5.0
VL < 50 copies/ml / CD4 ≥ 350 cells/mm3	36	69.2	136	81.0	172	78.2
VL ≥ 50 copies/ml / CD4 < 350 cells/mm3	4	7.7	7	4.2	11	5.0
VL ≥ 50 copies/ml / CD4 ≥ 350 cells/mm3	1	1.9	5	3.0	6	2.7
Not available	7	13.5	13	7.7	20	9.1
Antiretroviral therapy usec							0.457
No	5	9.6	11	6.5	16	7.3
Yes	47	90.4	157	93.5	204	92.7
Topography of lesions							0.313
Cephalic/neck	42	16.3	215	83.7	257	100.0
Torso	33	21.6	120	78.4	153	100.0
Genitals/buttocks	53	17.7	247	82.3	300	100.0
Extremities	36	22.6	123	77.4	159	100.0
Number of segments affected							0.238
One	41	48.2	152	49.2	193	49.0
Two	26	30.6	73	23.6	99	25.1
Three	11	12.9	46	14.9	57	14.5
Four	5	5.9	36	11.7	41	10.4
Ignored	2	2.4	2	0.6	4	1.0
Distribution of lesionsd							0.006
Only genitals/buttocks	27	32.5	128	41.7	155	39.7
Genitals/buttocks and extra-genitals	26	31.3	119	38.8	145	37.2
Only extra-genitals	30	36.1	60	19.5	90	23.1
Morphology of lesions							0.361
Macula	27	21.8	97	78.2	124	100.0
Papule	40	19.4	166	80.6	206	100.0
Vesicle	11	22.0	39	78.0	50	100.0
Pustule	29	14.1	177	85.9	206	100.0
Scab	41	20.1	163	79.9	204	100.0
Number of lesions							0.596
Single	12	14.1	37	12.0	49	12.4
Multiple	73	85.9	272	88.0	345	87.6
Stage of lesions							0.055
Single-phase	31	36.5	80	25.9	111	28.2
Polymorphic	54	63.5	229	74.1	283	71.8
Other signs and symptoms							0.664
Adenomegaly	28	10.7	233	89.3	261	100.0
Fever	16	8.5	172	91.5	188	100.0
Headache	20	10.9	163	89.1	183	100.0
Myalgia	22	12.8	150	87.2	172	100.0
Asthenia	22	13.2	145	86.8	167	100.0
Back pain	14	14.0	86	86.0	100	100.0
Number of other signs and symptoms							<0.001
None	32	37.6	24	7.8	56	14.2
1 to 3	41	48.2	155	50.2	196	49.7
4 or more	12	14.1	130	42.1	142	36.0
STI last 12 months							0.144
No	78	91,8	265	85.8	343	87.1
Yes	7	8.2	44	14.2	51	12.9
Concurrent STI							0.037
No	74	87.1	290	93.9	364	92.4
Yes	11	12.9	19	6.1	30	7.6
Number of sexual partnerse							0.158
None	7	10.1	16	6.5	23	7.3
1	31	44.9	81	32.8	112	35.4
2 to 5	20	29.0	107	43.3	127	40.2
6 to 10	5	7.2	25	10.1	30	9.5
11 or more	6	8.7	18	7.3	24	7.6
Presumed transmission route							0.086
Sexual	81	95.3	304	98.4	385	97.7
Healthcare associated	1	1.2	0	0.0	1	0.3
Non-sexual contact	3	3.5	5	1.6	8	2.0

PrEP: HIV pre-exposure prophylaxis; STI: sexually transmitted infection; VL: viral load.

Comparisons performed using chi-square tests. Bold indicates statistically significant difference (P <0.05).

^aIgnored for three patients

^bIgnored for 20 patients

^cNot applicable for 174 patients

^dIgnored for four patients

^eIgnored for 78 patients.